Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
Holding NGNE?
Track your performance easily
NGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.49 - $55.21
Previous Close$44.01
Volume107.27K
Average Volume (3M)108.97K
Market Cap
$571.85M
Enterprise Value$431.73M
Total Cash (Recent Filing)$153.91M
Total Debt (Recent Filing)$13.79M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 09, 2024EPS Estimate
-$1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.71
Shares Outstanding12,993,613
10 Day Avg. Volume95,697
30 Day Avg. Volume108,966
Standard Deviation0.29
R-Squared0.07
Alpha0.00988
Financial Highlights & Ratios
Price to Book (P/B)3.67
Price to Sales (P/S)634.23
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue466.73
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.03
Forecast
1Y Price Target
$56.00Price Target Upside27.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Neurogene News
PremiumCompany Announcements
Neurogene Secures $200M for Genetic Therapy Development
PremiumCompany Announcements
Neurogene’s NGN-401 Wins Key FDA Designation
PremiumCompany Announcements
Neurogene’s NGN-401 Shows Promise for Rett Syndrome
PremiumCompany Announcements
Neurogene’s NGN-401 Granted RMAT Status for Rett SyndromeBulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment is complete in the Phase 1/2 trial of NGN-101 in CLN5 Batten disease with interim clinical data expected and a regulatory update that will likely determine the future of this program.
Financial StabilityNeurogene ended 2Q24 with $154M in cash, which the company continues to expect to be sufficient into 2H26.
Regulatory ApprovalRecent RMAT designation, along with FDA's START designation, gives the opportunity for accelerated approval and suggests preliminary clinical data appears promising.
Bears Say
Adverse EventsOne pediatric patient experienced two SAEs related to underlying disease/immunosuppression regimen.
Clinical DataThe clinical data update on TSHA-102 was inconclusive, and NGNE stock weakness is understood in sympathy to TSHA.
EfficacyThree of the four patients showed a worsening in their Rett Syndrome Behavior Questionnaire (RSBQ) score for at least one time point compared to baseline.
---
Ownership Overview
4.06% Insiders
13.91% Mutual Funds
<0.01% Other Institutional Investors
69.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $12.49 and its highest was $55.20 in the past 12 months.
What is Neurogene’s market cap?
Currently, no data Available
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Aug 09, 2024 which is 88 days ago.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on May 10, 2024. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.034 by $0.034.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -$1.05.
How many shares outstanding does Neurogene have?
Neurogene has 12,993,613 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1 in its last earnings report, beating expectations of -$1.034. Following the earnings report the stock price went down -2.627%.
Which hedge fund is a major shareholder of Neurogene?
Among the largest hedge funds holding Neurogene’s share is Baker Bros Advisors LP. It holds Neurogene’s shares valued at 17M.
---
Neurogene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.00 (27.24% Upside)
$56.00 (27.24% Upside)
Blogger Sentiment
Bullish
NGNE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 56.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
225.51%
12-Months-Change
Fundamentals
Return on Equity
-47.27%
Trailing 12-Months
Asset Growth
91.29%
Trailing 12-Months
Company Description
Neurogene
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
---
NGNE Stock 12 Month Forecast
Average Price Target
$56.00
▲(27.24% Upside)
Technical Analysis
Best Analysts Covering NGNE
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+41.27%
reiterated a buy rating 3 months ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +41.27% per trade.
---